Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Honliv Healthcare Management Group Company Limited
宏力醫療管理集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9906)

RESUMPTION GUIDANCE AND SUSPENSION OF TRADING

This announcement is made by the Board of Directors (the "**Board**") of Honliv Healthcare Management Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 19 March 2026, 25 March 2026 and 21 April 2026, in relation to, among other things, (i) the delay in publishing the Company's audited annual results for the year ended 31 December 2025; (ii) the resignation of its then auditors PricewaterhouseCoopers ("**PwC**"); and (iii) suspension of trading (collectively, the "**Announcements**"). Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

RESUMPTION GUIDANCE

On 13 May 2026, the Company received a letter from the Stock Exchange setting out the guidance for resumption of trading in the shares of the Company on the Stock Exchange (the "**Resumption Guidance**"). Pursuant to the Resumption Guidance, the Company shall:

(a) conduct an appropriate independent forensic investigation into the Loan, the transfer of the proceeds from the Loan to a construction company, the receipts of bank transfers and partial repayments of the loan by Honliv Hospital, and any other loans or arrangements of a similar nature or giving rise to similar concerns, assess the impact on the Company's business operations and financial position, announce the findings and take appropriate remedial actions;

(b) demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence;

(c) engage an independent internal control consultant to conduct an independent internal control review and demonstrate that:

  (i) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and

  (ii) the internal controls of the Company are adequate and effective to serve their purposes and enable the issuer to comply with the Listing Rules in all material aspects, including but not limited to financial reporting, cash management, disclosure and compliance relating to notifiable and connected transactions and disclosure of material information;

(d) publish all outstanding financial results required under the Listing Rules and address any audit modifications;

(e) demonstrate the Company's compliance with Rule 13.24; and

(f) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position.

Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on 19 September 2027. If the Company fails to remedy the issues causing its trading suspension, fulfil the Resumption Guidance and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares by 19 September 2027, the Listing Division of the Stock Exchange will recommend the Listing Committee of the Stock Exchange to proceed with the cancellation of the Company's listing. Under Rules 6.01 and 6.10 of the Listing Rules, the Stock Exchange also has the right to impose a shorter specific remedial period or to cancel the listing of the Company immediately, where appropriate.

The Company is taking appropriate steps to comply with the Resumption Guidance and will seek to resume trading of its shares as soon as possible. The Company will keep the Shareholders and potential investors informed of the latest progress as and when appropriate and will announce quarterly updates on its development pursuant to Rule 13.24A of the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:00 a.m. on 20 March 2026 and will remain suspended until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Honliv Healthcare Management Group Company Limited
Qin Yan
Chairman

Hong Kong, 18 May 2026

As at the date of this announcement, the Board comprises Mr. Qin Yan, Mr. Wang Zhongtao and Ms. Li Yanhong as the executive directors; Mr. Qin Hongchao as the non-executive director; and Mr. Zhao Chun, Mr. Sun Jigang and Mr. Jiang Tianfan as the independent non-executive directors.